RESUMEN
Objective: The present study was conducted to determine the level of awareness about the difference between short-acting opioid (SAO) and rapid-onset opioid (ROO) formulation. Methods: A questionnaire survey was conducted to evaluate levels of awareness regarding the definition of cancer breakthrough pain, how to use the ROO formulation, and the difference between SAO and ROO formulation among physicians, nurses, and pharmacists. The surveillance period is between December 1, 2017 and December 31, 2017. Results: We received responses from 35 physicians, 102 nurses, and 171 pharmacists. The awareness of the difference between SAO formulation and ROO formulation across all occupation groups was approximately 3.8 in 11 steps from 0 to 10. Regarding the appropriate use of the ROO formulation, there was a tendency for variation among respondents in awareness about items referring to “the starting dose” and “the starting dose does not depend on the daily dose of the opioid analgesic administered on time.” Conclusion: The results of the present study suggest that it is necessary for each healthcare professional to reconfirm their knowledge of ROO formulation in the future and ensure appropriate administration.